Can you stay on Mounjaro for life? What the evidence says

Staying on Mounjaro for life: what the licence says, and what it doesn't

Mounjaro's UK licence contains no upper time boundary. Eli Lilly's authorisation covers adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition, for as long as the treatment remains clinically appropriate. That phrase matters. The licence does not guarantee indefinite supply, it leaves duration in the hands of a prescriber, which is exactly where it belongs.

NICE's appraisal of tirzepatide (TA1026, recommendations chapter) sets one practical checkpoint: if a person has not lost at least 5% of their body weight after six months on the highest dose they can tolerate, continuing is reviewed. That is a performance threshold, not a calendar cut-off. If you are responding well, there is no NICE rule that ends treatment at year one or year three.

The more relevant question for most people is not the licence, it is what happens to weight when the medicine stops. The tirzepatide clinical programme consistently shows that body weight tends to drift back toward pre-treatment levels once injections cease, because the underlying biology (appetite regulation, metabolic rate, gut-hormone signalling) reasserts itself. That is not a failure of willpower. It reflects how obesity works as a long-term condition, and it is one of the main reasons prescribers and patients often plan for extended treatment rather than a fixed course.

What makes long-term use clinically suitable for you specifically?

Deciding whether you can stay on Mounjaro for life is genuinely individual. A prescriber weighing this up will look at several things alongside the obvious weight metric.

Ongoing benefit is the first. If the medicine continues to support meaningful weight maintenance or loss, continuation is usually straightforward to justify. If progress has plateaued significantly and other factors outweigh the benefits, a prescriber may discuss alternatives or a structured pause.

Tolerability across time also matters. Most people find that the gastrointestinal side effects (nausea, loose stools, reduced appetite) are strongest in the early months and settle considerably by the time they reach a stable dose. Long-term safety data from the SURMOUNT clinical programme (involving thousands of adults across the trials) and from real-world use since UK approval is, so far, reassuring, though Mounjaro still carries a Black Triangle (▼) status indicating that the MHRA continues active monitoring.

Your other health conditions and medicines form a third layer. Someone managing type 2 diabetes, cardiovascular risk and high blood pressure alongside their weight may have an even stronger case for long-term continuation than someone whose only indication is BMI alone. Conversely, changes in health (a new pregnancy, a shift in kidney function, a planned surgical procedure) may prompt a prescriber to pause or adjust. The NHS tirzepatide page covers contraindications and cautions in plain language if you want the full list before your next review.

Cost sits in this decision too, practically speaking. Private treatment runs month to month, and some people find they need to pause during a tight period (payday timing, a holiday, an unexpected bill) before resuming. That is a legitimate part of managing long-term private prescribing, and a good prescriber factors it in without judgment. You can find current treatment pricing and what is included at nume on the treatments page.

What happens if you stop, and is stopping reversible?

This is, genuinely, one of the most common questions a prescriber hears. The short answer is that stopping is physically safe, but the weight effects are usually not permanent once the medicine is withdrawn.

Data from tirzepatide extension studies mirrors what was seen with other GLP-1 medicines before it: participants who stopped treatment regained a significant proportion of the weight they had lost, typically within a year. The mechanisms are well understood, Mounjaro suppresses appetite partly by mimicking GIP and GLP-1 gut hormones; when the injections stop, that hormonal signal disappears and hunger levels tend to climb back toward baseline.

This does not mean stopping is irreversible in terms of health outcomes. People who stop after significant loss and adopt sustainable diet and activity habits may retain more of their progress than those who do not. But the idea that a finite course permanently resets metabolism is not supported by current evidence.

What this means practically is that the question of whether to stay on Mounjaro long-term is less about a finish line and more about an ongoing clinical relationship. Our clinical team reviews every patient before each repeat supply, not to create hurdles, but because genuine clinical oversight is exactly what long-term safety requires. If you are weighing whether staying on Mounjaro long-term is right for you, that conversation belongs with a prescriber who knows your full picture.

Keeping long-term treatment safe and genuinely supervised

Long-term use of any prescription medicine calls for more rigour, not less, as time goes on. A few things are worth building into how you manage ongoing Mounjaro treatment.

First, keep weight records. Prescribers reviewing long-term continuation need to see that treatment is still doing meaningful work. At nume, live weight verification is part of our standard review process, not a tick-box, but an actual clinical checkpoint.

Second, keep your GP informed. The GPhC expects private prescribers to notify GPs in line with professional guidance, and nume does this routinely. Your GP seeing the full picture means drug interactions, new diagnoses and repeat prescriptions for other medicines are all handled safely.

Third, if you are also using oral contraception, MHRA and NHS guidance recommends adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption. This applies specifically to tirzepatide, discuss it with your GP or prescriber if you have not already.

Curious about the broader landscape of long-term tirzepatide treatment or how the evidence compares across weight-management medicines? Our weight-loss treatments overview covers that ground, and if you have questions about whether you can be on Mounjaro for life or want to understand more about what taking Mounjaro for life actually involves, our FAQs address many of the things people ask us most.